MX2023006153A - Terapias genicas para enfermedad neurodegenerativa. - Google Patents
Terapias genicas para enfermedad neurodegenerativa.Info
- Publication number
- MX2023006153A MX2023006153A MX2023006153A MX2023006153A MX2023006153A MX 2023006153 A MX2023006153 A MX 2023006153A MX 2023006153 A MX2023006153 A MX 2023006153A MX 2023006153 A MX2023006153 A MX 2023006153A MX 2023006153 A MX2023006153 A MX 2023006153A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- neurodegenerative disease
- apoe
- gene therapies
- disclosure provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118060P | 2020-11-25 | 2020-11-25 | |
| PCT/US2021/060731 WO2022115535A1 (en) | 2020-11-25 | 2021-11-24 | Gene therapies for neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006153A true MX2023006153A (es) | 2023-07-18 |
Family
ID=81754891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006153A MX2023006153A (es) | 2020-11-25 | 2021-11-24 | Terapias genicas para enfermedad neurodegenerativa. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230405149A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4251276A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551254A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230112672A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116670291A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021386390A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203006A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303156A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006153A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022115535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220107243A (ko) | 2019-11-25 | 2022-08-02 | 코넬 유니버시티 | Apoe 유전자 요법 |
| WO2024220726A1 (en) * | 2023-04-18 | 2024-10-24 | Cornell University | Methods and apoe pharmaceutical compositions for the treatment and the prevention of alzheimers disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023587A2 (en) * | 1998-10-16 | 2000-04-27 | Introgene B.V. | Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e |
| ATE387459T1 (de) * | 2000-04-06 | 2008-03-15 | Kos Pharma Inc | Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie |
| US20150183850A1 (en) * | 2012-05-18 | 2015-07-02 | University Of Iowa Research Foundation | Methods and compositions for treating amyloid deposits |
| CA3121211A1 (en) * | 2018-11-28 | 2020-06-04 | Prevail Therapeutics, Inc. | Gene therapies for neurodegenerative disease |
| KR20220107243A (ko) * | 2019-11-25 | 2022-08-02 | 코넬 유니버시티 | Apoe 유전자 요법 |
-
2021
- 2021-11-24 KR KR1020237020920A patent/KR20230112672A/ko not_active Withdrawn
- 2021-11-24 IL IL303156A patent/IL303156A/en unknown
- 2021-11-24 EP EP21899082.8A patent/EP4251276A4/en active Pending
- 2021-11-24 JP JP2023532127A patent/JP2023551254A/ja active Pending
- 2021-11-24 US US18/038,247 patent/US20230405149A1/en active Pending
- 2021-11-24 AU AU2021386390A patent/AU2021386390A1/en not_active Abandoned
- 2021-11-24 CN CN202180087728.0A patent/CN116670291A/zh not_active Withdrawn
- 2021-11-24 MX MX2023006153A patent/MX2023006153A/es unknown
- 2021-11-24 WO PCT/US2021/060731 patent/WO2022115535A1/en not_active Ceased
- 2021-11-24 CA CA3203006A patent/CA3203006A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021386390A1 (en) | 2023-06-29 |
| CN116670291A (zh) | 2023-08-29 |
| IL303156A (en) | 2023-07-01 |
| JP2023551254A (ja) | 2023-12-07 |
| KR20230112672A (ko) | 2023-07-27 |
| CA3203006A1 (en) | 2022-06-02 |
| EP4251276A1 (en) | 2023-10-04 |
| EP4251276A4 (en) | 2024-10-23 |
| US20230405149A1 (en) | 2023-12-21 |
| WO2022115535A1 (en) | 2022-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| JP2023011696A (ja) | 核酸産物およびその投与方法 | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| ATE280590T1 (de) | Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen | |
| EA202090817A1 (ru) | Триспецифические белки и способы их применения | |
| MX2021012184A (es) | Terapias genicas para trastornos lisosomales. | |
| Dagil et al. | The dual NOD1/NOD2 agonism of muropeptides containing a meso-diaminopimelic acid residue | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| WO2020186207A3 (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
| PH12021551135A1 (en) | Rna encoding a protein | |
| MX2022013525A (es) | Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas. | |
| JP2022513618A (ja) | 血液脳関門の標的化に有用な組成物および方法 | |
| MX2025009545A (es) | Metodos y composiciones para la administracion de sistemas de vector dual otoferlin | |
| MX2024003519A (es) | Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso. | |
| WO2021030766A8 (en) | Combination therapy for spinal muscular atrophy | |
| MX2022011805A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix. | |
| MX2025012376A (es) | Métodos y composiciones farmacéuticas de apoe para el tratamiento y la prevención de enfermedad de alzheimer | |
| WO2022182864A8 (en) | Prion protein (prnp) irna compositions and methods of use thereof | |
| MX2022011806A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos contra gaucher. | |
| Zhang et al. | MLKL-USP7-UBA52 signaling is indispensable for autophagy in brain through maintaining ubiquitin homeostasis | |
| ATE365807T1 (de) | Hepatitis b virus vektoren für gentherapie | |
| MX2025000757A (es) | Casetes reguladores específicos del músculo | |
| PH12022550977A1 (en) | Compositions and methods for treating glycogen storage disorders | |
| MX2025000200A (es) | Metodos y composiciones farmaceuticas para el tratamiento y la prevencion de la enfermedad de alzheimer | |
| CO6160332A2 (es) | Agente para terapia y/o mejoramiento de coagulacion intravascular diseminada |